Strengthening the role of artificial intelligence in oncology, Bristol Myers Squibb (BMS) has announced a strategic collaboration with Microsoft to accelerate the early detection of lung cancer. The agreement focuses on deploying AI-enabled radiology solutions to support clinicians in identifying the disease at earlier and more treatable stages.
Deploying FDA-Cleared AI Radiology Tools
As part of the collaboration, the companies will deploy U.S. Food and Drug Administration–cleared radiology AI algorithms through Microsoft’s Precision Imaging Network. This platform analyzes X-ray and CT images to help identify lung disease and is already in use across hospitals in the United States. Consequently, the partnership aims to integrate advanced imaging intelligence seamlessly into existing clinical workflows.
Improving Detection of Hard-to-Identify Lung Nodules
As reported by Reuters, Bristol Myers Squibb stated that these AI-driven tools can help clinicians spot hard-to-detect lung nodules and identify patients at earlier stages of disease. By enhancing diagnostic accuracy and speed, the technology has the potential to significantly improve patient outcomes.
Expanding Access in Underserved Communities
Importantly, a key objective of the partnership is to expand access to early lung cancer detection in medically underserved communities. This includes reaching rural hospitals and community clinics across the United States, where access to specialised diagnostic tools often remains limited.
Integrating Oncology Expertise with Scalable AI
Commenting on the collaboration, Alexandra Goncalves, Vice President and Head of Digital Health at Bristol Myers Squibb, said the partnership brings together complementary strengths.
“By combining Microsoft’s highly scalable radiology solutions with Bristol Myers Squibb’s deep expertise in oncology and drug delivery, we have envisioned a unique AI-enabled workflow that helps clinicians quickly and accurately identify patients with non-small cell lung cancer and guide them to optimal care pathways and precision therapies,” she said.
Growing Use of AI Across Pharma R&D
More broadly, pharmaceutical companies are increasingly turning to artificial intelligence to accelerate research and development, betting that advanced modelling tools and automated laboratories can improve efficiency across drug development pipelines. For instance, AstraZeneca recently announced its agreement to acquire Boston-based Modella AI to further speed up oncology drug research.
Together, these developments highlight how AI is rapidly reshaping cancer detection, diagnosis, and drug discovery across the global healthcare landscape.